• news.cision.com/
  • H. Lundbeck A/S/
  • H. Lundbeck, Lundbeck and Merck & Co., Inc. announce alliance to develop and commercialize gaboxadol in the United States
English

H. Lundbeck, Lundbeck and Merck & Co., Inc. announce alliance to develop and commercialize gaboxadol in the United States

Report this content 

                        
H. Lundbeck A/S and Merck & Co., Inc. today announced an agreement, through wholly-owned affiliates, for the exclusive US development and commercialization of gaboxadol, a compound currently in phase III development for the treatment of sleep disorders.




                                            

                

            

        

    

    



    

        
 Subscribe

        

            

        

    


        

            
        

        

            
        

        



    

        
 Documents & Links